OAM
MRNA icon

Oxford Asset Management’s Moderna MRNA Stock Holding History

Oxford Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-33,765
Closed -$660K – 868
2019
Q4 		$660K Buy
33,765
+14,403
+74% +$256K 0.02% 1089
2019
Q3 		$308K Buy
+19,362
New +$286K 0.01% 1449

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Oxford Asset Management's MRNA Position: Q1 2020 in Review

Oxford Asset Management sold out of Moderna (MRNA) in Q1 2020, closing a stake of 33,765 shares — an estimated $660K sold.

Oxford Asset Management first reported a position in MRNA in Q3 2019 and held it in 2 quarters. The position peaked at $660K in Q4 2019. 299 funds tracked by Wall St. Rank hold MRNA as of Q1 2020.

  • Oxford Asset Management reported no remaining Moderna position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 33,765 Moderna shares in Q1 2020, an estimated $660K.
  • Oxford Asset Management first reported a position in Moderna in Q3 2019 and held it in 2 quarters.
  • Oxford Asset Management's Moderna position peaked at $660K in Q4 2019.
  • 299 funds tracked by Wall St. Rank held Moderna as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.